Literature DB >> 57102

[A new instruction theory: possibility of a reverse flow of information from polypeptide sequences to RNA particularly in antibody synthesis, and the mechanisms of tolerance induction and immunosuppression (author's transl)].

K Theurer.   

Abstract

A new instruction theory for antibody formation is presented. The reverse flow of information from the amino-acid sequences of small antigenic determinants to an antideterminant RNA (aRNA) seems feasible. Prerequisites are specific activating enzymes, tRNAs, ATP as well as some kind of membrane assembling the anticodons of tRNAs linearly, analogous to the linear primary structure of stretched polypeptides. Once synthesized, aRNA might be replicated, utilized as transfer factor and transcribed by means of Reverse Transcriptase into aDNA. Further steps would be the fusion of this aDNA with genetical performed DNA-molecules already coding for the basic strucures of different classes of immunoglobulins by means of a terminal deoxynucleotidyl-transferase. This could be a chromosomal or extrachromosomal integration. The second hypothesis concerns antigen-induced immunosuppression and the phenomenon of nonresponsiveness (tolerance). An overwhelming proteolysis might give rise to a degradation of antigens or receptor templates for antigenic determinants located on the surface of macrophages. On later exposure to a similar antigen proteolytic enzymes are already preformed abolishing rapidly antigenic information. The third hypothesis concerns antibody-induced immunosuppression and tolerance. Antideterminant information is integrated into the genome or established extra-chromosomally. The continuous presence of antibodies sets in motion a sequence of reactions causing an accumulation of all information intermediates including a complementary DNA strand to the aRNA. On exposure to the corresponding antigen aRNA is transcribed. However, translation might be inhibited by hybridisation with the complementary aDNA strand as well as specific RNA hydrolysis by RNase H. Concerning the immunogenity of antibodies, a proteolytical mechanism might also be possible. Taking this into account a tolerance could be suspended in the following way: 1. by influencing the overwhelming proteolytical degradation of antigenic determinants with simultaneous antigenic stimulation; 2. by substitution of aRNA to induce blocked antibody synthesis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 57102     DOI: 10.1007/bf01641347

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  8 in total

1.  [Anti-sensitization as a new method of desensitization].

Authors:  K THEURER
Journal:  Medizinische       Date:  1956-11-03

2.  RNA in the in vitro immune response. Flow of information and gene activation during antibody synthesis.

Authors:  D Jachertz
Journal:  Ann N Y Acad Sci       Date:  1973-05-31       Impact factor: 5.691

3.  RNA-dependent DNA polymerase in human lymphocytes during gene activation by phytohaemagglutinin.

Authors:  P E Penner; L H Cohen; L A Loeb
Journal:  Nat New Biol       Date:  1971-07-14

4.  Ribonuclease H. An enzyme degrading the RNA moiety of DNA-RNA hybrids.

Authors:  P Hausen; H Stein
Journal:  Eur J Biochem       Date:  1970-06

5.  The molecular basis of immunity.

Authors:  F Haurowitz
Journal:  Ann N Y Acad Sci       Date:  1970-02-13       Impact factor: 5.691

6.  Gene amplification in cell-free systems.

Authors:  D Jacherts; U Opitz; H G Opitz
Journal:  Z Immunitatsforsch Exp Klin Immunol       Date:  1972-10

7.  RNA dependent DNA polymerase activity in mammalian cells.

Authors:  E M Scolnick; S A Aaronson; G J Todaro; W P Parks
Journal:  Nature       Date:  1971-01-29       Impact factor: 49.962

8.  A new synthetic RNA-dependent DNA polymerase from human tissue culture cells (HeLa-fibroblast-synthetic oligonucleotides-template-purified enzymes).

Authors:  B Fridlender; M Fry; A Bolden; A Weissbach
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.